Trial Profile
Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Anti CD22 chimeric antigen receptor T cell therapy-Shanghai Unicar-Therapy Bio-medicine Technology (Primary) ; Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary) ; Cyclophosphamide; Decitabine; Fludarabine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 27 Nov 2023 Planned End Date changed from 1 Jan 2024 to 31 Dec 2025.
- 27 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2024.
- 18 May 2022 Planned End Date changed from 1 Jan 2021 to 1 Jan 2024.